论文部分内容阅读
在急性白血病、非何杰金氏淋巴瘤及实体肿瘤病人,经过大剂量化疗和放疗处理后,应用自体血干细胞使血细胞再生已获成功。然而有些病人有不完全的血细胞植入,这就需要选择一个安全的最小原始血细胞量,它将在超致死量的治疗后产生完全的血细胞再生。46例进行过ABSCT病人的资料,回答了这个问题。 46例病人(中位年龄26岁;3.5-53岁),均系急性非淋巴细胞性白血病、急性淋巴细胞性白血病、非何杰金氏淋巴瘤。作者对这些进行ABSCT的病人采用了不同的处理方法:34例病人接受全身放疗(TBI,1000-1200 rads)。其中30例与环磷酰酗(120mg/kg)联用,3例与“BEAM”(BCNU,鬼臼乙叉
In acute leukemias, non-Hodgkin’s lymphoma and solid tumor patients, hematopoietic stem cells have been used to regenerate blood cells after high-dose chemotherapy and radiotherapy. However, some patients have incomplete blood cell engraftment, which requires the selection of a safe minimum initial blood cell mass that will result in complete blood cell regeneration following a sublethal dose of treatment. 46 cases of patients with ABSCT data to answer this question. Forty-six patients (median age 26 years; 3.5-53 years) were all acute non-lymphocytic leukemia, acute lymphoblastic leukemia and non-Hodgkin’s lymphoma. The authors used different treatments for these patients undergoing ABSCT: 34 patients received systemic radiotherapy (TBI, 1000-1200 rads). Of these, 30 were combined with cyclophosphamide (120 mg / kg), and 3 were associated with “BEAM” (BCNU,